By Fineline Cube 
Merck & Co., Inc. (MSD, NYSE: MRK) announced that the European Commission has granted marketing authorization for KEYTRUDA (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, for the treatment of platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma in adults whose tumors express PD-L1 with a Combined Positive Score (CPS) ≥1 and who have received one or two prior systemic treatment regimens.
Regulatory Approval Details
| Item | Detail |
|---|---|
| Company | Merck & Co., Inc. (MSD) |
| Stock Code | NYSE: MRK |
| Approved Product | KEYTRUDA (pembrolizumab) |
| Formulations | Intravenous and subcutaneous (KEYTRUDA SC/KEYTRUDA QLEXTM) |
| Indication | Platinum-resistant ovarian cancer (epithelial ovarian, fallopian tube, primary peritoneal) |
| Patient Population | PD-L1 CPS ≥1, 1-2 prior systemic treatments |
| Regulatory Body | European Commission |
| CHMP Recommendation | February 2026 |
Clinical Evidence – Phase 3 KEYNOTE-B96 Trial
| Endpoint | KEYTRUDA + Paclitaxel ± Bevacizumab | Placebo + Paclitaxel ± Bevacizumab | Statistical Significance |
|---|---|---|---|
| Progression-Free Survival (PFS) | Primary endpoint met | Control arm | Statistically significant improvement |
| Overall Survival (OS) | Key secondary endpoint | Control arm | Clinically meaningful improvement |
| Trial Designation | KEYNOTE-B96 / ENGOT-ov65 | Phase 3 randomized controlled trial | Global multi-center study |
| Patient Population | Platinum-resistant recurrent ovarian cancer, PD-L1 CPS ≥1 | Same criteria | Biomarker-selected population |
The approval represents a landmark achievement as this regimen becomes the first and only PD-1 inhibitor-based treatment option for eligible patients with platinum-resistant ovarian cancer in the European Union.
Market Impact & Therapeutic Significance
- Unmet Medical Need: Platinum-resistant ovarian cancer has limited treatment options with poor prognosis; median survival typically less than 12 months
- Biomarker Strategy: PD-L1 CPS ≥1 selection enables precision medicine approach, potentially improving outcomes for biomarker-positive patients
- Administration Flexibility: Approval covers both intravenous and subcutaneous formulations, offering dosing convenience through KEYTRUDA SC
- Competitive Positioning: Establishes Merck as the first PD-1 inhibitor provider in the EU platinum-resistant ovarian cancer market
- Revenue Potential: Expands KEYTRUDA’s oncology footprint into gynecological cancers, complementing existing approvals in cervical and endometrial cancers
Strategic Implications for Merck
- KEYTRUDA Portfolio Expansion: Strengthens Merck’s position in women’s health oncology alongside existing gynecological cancer indications
- Global Development: EU approval follows positive CHMP recommendation and may inform regulatory strategies in other regions
- Combination Therapy Leadership: Reinforces Merck’s expertise in developing effective immunotherapy combinations across tumor types
- Commercial Execution: Merck will leverage existing oncology infrastructure to rapidly implement access programs across EU member states
Forward-Looking Statements
This brief contains forward-looking statements regarding Merck’s regulatory approvals, clinical development plans, and commercial expectations for KEYTRUDA. Actual results may differ materially due to risks including market adoption, competitive dynamics, reimbursement decisions, and post-marketing requirements.-Fineline Info & Tech